InvestorsHub Logo
Followers 49
Posts 4907
Boards Moderated 1
Alias Born 01/05/2005

Re: None

Monday, 03/12/2007 3:38:44 PM

Monday, March 12, 2007 3:38:44 PM

Post# of 1171
US demand for nanotechnology medical products to approach $53 billion in 2011

Cleveland, OH
Posted on March 12th, 2007

The critical need for new or improved therapies for many medical conditions will
promote the adaptation of nanotechnology to an expanding number of
pharmaceuticals. The total market for nanomedicines will command strong growth
over the long term. Treatments based on humanized monoclonal antibodies,
nanopolymers and nanoproteins will drive gains, with compounds for cancer, heart
diseases, neurological disorders and viral infections leading new product introductions
and growth opportunities.

Advances in nanotechnology will also contribute significant improvements to the
quality and performance of medical diagnostic products. Nanosized monoclonal
antibody labels and DNA probes will greatly enhance the speed, accuracy, capabilities
and cost-effectiveness of in vitro diagnostic testing, drug discovery and medical
research procedures. Nanoparticle formulations of superparamagnetic iron oxide,
gadolinium, perfluorocarbon and specialty polymers will broaden in vivo imaging
capabilities. Several medical supplies and devices will emerge as key applications
for nanotechnology. Nanomaterials are already gaining significant demand as active
ingredients of burn dressings, bone cement, bone substitutes, and dental repair and
restoration products.

The greatest short-term impact of nanotechnology in health care will be in
therapies and diagnostics for cancer and central nervous system disorders.
Gradually, many other major diseases, as well as injuries, will be treated and detected
routinely by nanotechnology products. By 2016, nanoimplants will be widely employed
in orthopedic procedures and begin to gain experimental uses in tissue and neuron
regeneration. By 2021, nanotechnology will serve applications that extend into most
areas of critical and chronic care. Additionally, the development of monoclonal antibody and nanomaterial vaccines and, to a lesser extent, controlled-release nutritional preparations will create a large preventive medicine market.




####

About Nanotechnology in Healthcare
Nanotechnology in Healthcare (published 02/2007, 349 pages) is available for $4,500 from The Freedonia Group, Inc., 767 Beta Drive, Cleveland, OH 44143-2326. For further details, please contact Corinne Gangloff by phone 440.684.9600, fax 440.646.0484 or e-mail pr@freedoniagroup.com.

A limited license to use or reprint information from this news release is granted to you provided attribution for the same – including, if possible, the price of the report – is given to The Freedonia Group, Inc. (Cleveland, OH). We would also appreciate the courtesy of receiving a copy of the article or publication in which we appear.

For more information, please click here

Contacts:
Corinne Gangloff
phone 440.684.9600
fax 440.646.0484
pr@freedoniagroup.com

Copyright © The Freedonia Group, Inc

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.